Moderna

MRNAPhase 2

Moderna, Inc. is a biotechnology company that harnesses the fundamental role of mRNA to translate genes into proteins to develop a new generation of transformative medicines for patients. The company created one of the most effective COVID-19 vaccines and has built a diverse development pipeline of mRNA medicines across multiple therapeutic areas. Moderna's platform approach enables rapid development of new treatments and vaccines by programming cells to produce therapeutic proteins.

Market Cap

$20.4B

Employees

4,000-5,000

Focus

Biotech

MRNA · Stock Price

USD 51.38114.54 (-69.03%)

Historical price data

AI Company Overview

Technology Platform

Messenger RNA (mRNA) platform that instructs cells to produce therapeutic proteins, utilizing proprietary lipid nanoparticle delivery systems for targeted drug delivery.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
VX-522 mRNA therapy + IVA	Cystic Fibrosis	Phase 1/2

Funding History

Total raised: $1.2B

IPO$604MUndisclosedDec 7, 2018

Series B$450MAstraZenecaJun 15, 2015

Series A$110MFlagship PioneeringJun 15, 2013

Seed$40MFlagship PioneeringJun 15, 2011

Opportunities

Moderna has significant growth opportunities through its diverse mRNA pipeline spanning multiple therapeutic areas, potential for recurring COVID-19 vaccine revenue, and expansion into international markets.

The company's platform approach enables rapid development of new treatments across oncology, rare diseases, and infectious diseases.

Risk Factors

Key risks include increasing competition in mRNA technology, regulatory challenges for new programs, and significant dependence on COVID-19 vaccine revenue.

The company also faces potential manufacturing scale-up challenges and pricing pressures in various markets.

Competitive Landscape

Moderna competes primarily with BioNTech/Pfizer in mRNA vaccines, traditional vaccine manufacturers like GSK and Merck, and various oncology and rare disease companies. The company differentiates through its comprehensive mRNA platform, proven manufacturing capabilities, and diverse pipeline across multiple therapeutic areas.

Publications

Patents

Pipeline